People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2012 |
| Rubius Therapeutics, Inc. | — | Biotechnology | Series D+ | $216.2M | $4.2B | 2017 |
| Cibo Technologies, Inc. | — | Software / Tech | Series B | $47.4M | $305.2M | 2017 |
| Eleven Biotherapeutics, Inc. | — | Biotechnology | Series B | $43.3M | $39.5M | 2010 |
| Helicos Biosciences Corp | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
Noubar B Afeyan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Noubar B Afeyan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Robert S Langer | 1 | 14 |
| Peter Barton Hutt | 1 | 14 |
| Amir Nashat | 1 | 14 |
| Srinivas Akkaraju | 1 | 10 |
| Mark Levin | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| Daniel S. Lynch | 1 | 6 |
| Vicki Sato | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Stanley N. Lapidus | 1 | 4 |
| MARTIN TAYLOR | 1 | 4 |
| Jorge Conde | 1 | 4 |
| Stephane Bancel | 1 | 4 |
| Daniel Ryan | 1 | 4 |
| Robert F Higgins | 1 | 3 |
| Kim C. Drapkin | 1 | 3 |
| Gregory D. Perry | 1 | 3 |
| Robert E. Nelsen | 1 | 3 |
| Peter Wirth | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.